Regulus Therapeutics Inc.
RGLS
Rangering i aksjer
#17275
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aksjekurs
$8.16
Sist synkronisert: 2025-06-26
Markedsverdi
$234.57M
Endring (1 dag)
0.00%
Endring (1 år)
-88.86%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Aksjeprishistorikk for Regulus Therapeutics Inc. (RGLS)
Høyeste sluttskurs: $73.27 den 2024-11-01
Laveste sluttskurs: $21.00 den 2010-04-01
Laveste sluttskurs: $21.00 den 2010-04-01
Aksjeprishistorikk for Regulus Therapeutics Inc. fra 2010 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2024 | 113.53% |
| 2023 | 140.97% |
| 2022 | -61.38% |
| 2021 | -67.58% |
| 2020 | -13.91% |
| 2019 | 22.71% |
| 2018 | 12.94% |
| 2017 | 104.37% |
| 2016 | -25.20% |
| 2015 | -38.37% |
| 2014 | 34.13% |
| 2013 | 93.41% |
| 2012 | 67.05% |
| 2011 | 2.83% |
| 2010 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
